The impacts of patents and R&D spikes on firm performance: Evidence from US biopharmaceutical companies
碩士 === 元智大學 === 財務金融暨會計碩士班(會計學程) === 105 === Based on a sample of 789 firm-year observations of US biopharmaceutical companies between 2011 and 2015, this study investigates how patents, research and development (R&D) spikes affect business efficiency. Firstly, the dynamic data envelopment analy...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | en_US |
Published: |
2017
|
Online Access: | http://ndltd.ncl.edu.tw/handle/35743615391744669078 |
id |
ndltd-TW-105YZU05736002 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-105YZU057360022017-09-19T04:29:38Z http://ndltd.ncl.edu.tw/handle/35743615391744669078 The impacts of patents and R&D spikes on firm performance: Evidence from US biopharmaceutical companies 專利和研發投资尖峰對公司績效的影響——以美國生物製藥公司為例 Truong Hoang Tu Nhi 張黃秀兒 碩士 元智大學 財務金融暨會計碩士班(會計學程) 105 Based on a sample of 789 firm-year observations of US biopharmaceutical companies between 2011 and 2015, this study investigates how patents, research and development (R&D) spikes affect business efficiency. Firstly, the dynamic data envelopment analysis (DEA) model is adopted to evaluate the performance of US biopharmaceutical companies. Then, ordinary least squares (OLS) regressions are used to explore the effects of three patent-related variables (patent counts, citations and claims) and R&D spikes on corporate performance. This research finds positive impacts of patent counts, citations and claims on operating efficiency. In addition, the results show that R&D spikes have negative contemporaneous effects and time-lagged effects on corporate performance. Wei-Kang Wang 王維康 2017 學位論文 ; thesis 29 en_US |
collection |
NDLTD |
language |
en_US |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 元智大學 === 財務金融暨會計碩士班(會計學程) === 105 === Based on a sample of 789 firm-year observations of US biopharmaceutical companies between 2011 and 2015, this study investigates how patents, research and development (R&D) spikes affect business efficiency. Firstly, the dynamic data envelopment analysis (DEA) model is adopted to evaluate the performance of US biopharmaceutical companies. Then, ordinary least squares (OLS) regressions are used to explore the effects of three patent-related variables (patent counts, citations and claims) and R&D spikes on corporate performance. This research finds positive impacts of patent counts, citations and claims on operating efficiency. In addition, the results show that R&D spikes have negative contemporaneous effects and time-lagged effects on corporate performance.
|
author2 |
Wei-Kang Wang |
author_facet |
Wei-Kang Wang Truong Hoang Tu Nhi 張黃秀兒 |
author |
Truong Hoang Tu Nhi 張黃秀兒 |
spellingShingle |
Truong Hoang Tu Nhi 張黃秀兒 The impacts of patents and R&D spikes on firm performance: Evidence from US biopharmaceutical companies |
author_sort |
Truong Hoang Tu Nhi |
title |
The impacts of patents and R&D spikes on firm performance: Evidence from US biopharmaceutical companies |
title_short |
The impacts of patents and R&D spikes on firm performance: Evidence from US biopharmaceutical companies |
title_full |
The impacts of patents and R&D spikes on firm performance: Evidence from US biopharmaceutical companies |
title_fullStr |
The impacts of patents and R&D spikes on firm performance: Evidence from US biopharmaceutical companies |
title_full_unstemmed |
The impacts of patents and R&D spikes on firm performance: Evidence from US biopharmaceutical companies |
title_sort |
impacts of patents and r&d spikes on firm performance: evidence from us biopharmaceutical companies |
publishDate |
2017 |
url |
http://ndltd.ncl.edu.tw/handle/35743615391744669078 |
work_keys_str_mv |
AT truonghoangtunhi theimpactsofpatentsandrdspikesonfirmperformanceevidencefromusbiopharmaceuticalcompanies AT zhānghuángxiùér theimpactsofpatentsandrdspikesonfirmperformanceevidencefromusbiopharmaceuticalcompanies AT truonghoangtunhi zhuānlìhéyánfātóuzījiānfēngduìgōngsījīxiàodeyǐngxiǎngyǐměiguóshēngwùzhìyàogōngsīwèilì AT zhānghuángxiùér zhuānlìhéyánfātóuzījiānfēngduìgōngsījīxiàodeyǐngxiǎngyǐměiguóshēngwùzhìyàogōngsīwèilì AT truonghoangtunhi impactsofpatentsandrdspikesonfirmperformanceevidencefromusbiopharmaceuticalcompanies AT zhānghuángxiùér impactsofpatentsandrdspikesonfirmperformanceevidencefromusbiopharmaceuticalcompanies |
_version_ |
1718538420538572800 |